Prostate Cancer Clinical Trials

Castration-Resistant Prostate Cancer (ARC-6)

Overview

A Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant-based combination therapy in participants with metastatic castrate resistant prostate cancer.

Key Eligibility Criteria

Metastatic castrate-resistant prostate cancer while on anti-androgen treatment with castrate levels of testosterone (≤1.7 nmol/L or 50 ng/dL)
Naive to any prior treatment with immune checkpoint blockade therapy

ARC-6 Clinical Trial Locations

clinicaltrials.gov

Healthcare Professionals: to learn more about Arcus trials, email [email protected]

Patients and Caregivers: Talk to your doctor if you are interested in learning more about Arcus clinical trials.

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration or by any health authority.